Athira Pharma Inc
For the period ended May 29, 2025. Filed Apr 14, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 29, 2025 · Filed Apr 14, 2025
Use the contents to explore the available documents and sections.
Contents
Equity Granting Practices
Our board of directors or compensation committee, as applicable, does not grant equity awards on a predetermined schedule. Our grant committee, which consists of certain members of management and which has been delegated prescribed authority to grant equity awards to certain non-executive officer service providers, approves equity awards in advance, and such awards generally become effective on the first trading day of the following month. Awards to our non-employee directors are granted automatically pursuant to our outside director compensation policy. We have not granted, nor do we intend to grant, stock options in anticipation of the release of material, nonpublic information, and we have not taken, nor do we intend to take, material nonpublic information into account when determining the terms of stock options. Similarly, we have not timed, nor do we intend to time, the release of material, nonpublic information for the purpose of affecting the value of executive compensation or for any other purpose.
| Athira Pharma, Inc. | 48 | 2025 Proxy Statement |
|---|
The table below sets forth certain information regarding the grants of option awards to our named executive officers which occurred within the period beginning four business days before the filing of a Form 10-Q, Form 10-K, or the filing or furnishing of a Form 8-K that discloses material nonpublic information (other than an Item 5.02(e) Form 8-K that discloses a material new option award grant) and ending one business day after the filing or furnishing of such report, as required by Item 402(x) of Regulation S-K.
| Name | Grant Date | Number of securities underlying the award | Exercise price of the award ($/share) | Grant date fair value of the award(1) | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information |
|---|---|---|---|---|---|
| Mark Litton | February 15, 2024 | 650,000 | $3.66 | $1,885,000.00 | 0%(2) |
| Mark Litton | October 3, 2024 | 325,000 | $0.4257 | $106,407.93 | (1.45)%(3) |
| Mark Worthington | October 1, 2024 | 110,000 | $0.4499 | $38,033.82 | (1.45)%(3) |
| Kevin Church | October 1, 2024 | 110,000 | $0.4499 | $38,033.82 | (1.45)%(3) |
| (1) | In accordance with SEC rules, amounts in this column reflect the aggregate grant date fair value of stock options computed in accordance with ASC Topic 718, rather than the amounts paid or realized by the named executive officer. For a discussion of valuation assumptions, see Note 9 and the section titled “Stock-based Compensation” to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. |
| (2) | Calculated using the closing price of our common stock on NASDAQ on February 22, 2024 and February 23, 2024, of $3.93 and $3.93, per share, respectively. |
| (3) | Calculated using the closing price of our common stock on NASDAQ on October 7, 2024 and October 8, 2024, of $0.429 and $0.4228, per share, respectively. |
| Athira Pharma, Inc. | 49 | 2025 Proxy Statement |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.